Atrium Therapeutics, Inc.
RNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002093101
No open-market purchases or sales by Atrium Therapeutics, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q2 2026, worth $192.8M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Atrium Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 163 | 2 | 154 | −7 |
| Shares | 14.8M | 140.0K | 14.3M | −362.1K (−2.5%) |
| Value | $198.3M | $1.87M | $192.8M | −$3.70M (−1.9%) |
2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (39)
Institutions that held Atrium Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (46)
Institutions that held Atrium Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
Not filed for Q2 2026 yet (2)
Institutions that held Atrium Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Janus Henderson Group PLC | 139,973 | $1.87M |
| CWM, LLC | 21 | $281 |